Q3 2015 13F Holders as of 30 Sep 2015
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
129.96%
-
Total 13F principal
-
$241,761,170
-
Principal change
-
+$217,316,170
-
Total reported market value
-
$314,220,141
-
Number of holders
-
25
-
Value change
-
+$282,556,141
-
Number of buys
-
24
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q3 2015
As of 30 Sep 2015,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$241,761,170
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, CAMDEN ASSET MANAGEMENT L P /CA, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, Allianz Asset Management AG, LAZARD ASSET MANAGEMENT LLC, DEUTSCHE BANK AG\, HIGHBRIDGE CAPITAL MANAGEMENT LLC, PALISADE CAPITAL MANAGEMENT LLC/NJ, and BASSO CAPITAL MANAGEMENT, L.P..
This page lists
25
institutional bondholders reporting positions
for the Q3 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.